How Aging Cells May Trigger Heart Attacks and Strokes

Key Takeaways

• Loss of LATS1/2 triggers CD38 activation in senescent endothelial cells
• CD38 reprograms metabolism, driving inflammation and plaque instability
• Inhibiting CD38 reverses pro‑thrombotic effects in preclinical models
• Findings link cancer‑therapy‑induced senescence to cardiovascular risk
• Existing FDA‑approved CD38 drugs could be repurposed for plaque stabilization

Pulse Analysis

The study shines a light on a previously hidden axis of vascular biology: the LATS1/2‑CD38 pathway. By stripping endothelial cells of LATS1/2, researchers observed a shift toward senescence coupled with a surge in CD38 activity. This enzyme rewires cellular energy use, prompting the cells to release inflammatory signals that erode the fibrous cap of atherosclerotic plaques. The resulting plaque fragility makes clots more likely, turning a stable lesion into a ticking time‑bomb for heart attacks or strokes.

Beyond basic science, the findings have immediate clinical resonance. Many modern chemotherapies and targeted agents accelerate cellular senescence not only in tumors but also in healthy vasculature, a side effect that has long puzzled cardiologists. The MD Anderson team validated the molecular signature in human plaque samples, confirming that the same CD38‑driven metabolic fingerprint appears in patients. This creates a potential biomarker pipeline for identifying individuals at heightened thrombotic risk after cancer treatment, allowing earlier intervention and tighter cardiovascular monitoring.

Therapeutically, CD38 is already a druggable target; FDA‑approved antibodies and small‑molecule inhibitors exist for multiple myeloma and chronic lymphocytic leukemia. The preclinical reversal of plaque instability by CD38 blockade suggests a rapid repurposing opportunity. Pharmaceutical firms could leverage existing safety data to launch cardiovascular trials, while biotech startups may focus on next‑generation, vessel‑specific CD38 modulators. If successful, such therapies could reduce the incidence of acute coronary events, lower healthcare costs, and provide a new revenue stream for companies positioned at the intersection of oncology and cardiology.